West Nile Virus Study (WNV) - Catalog

Name

West Nile Virus Study (WNV)

Accession Number

HLB01941414a

Acronym

WNV

Related studies

BSI Study IDs

WNV2

Is public use dataset

False

Keywords

Has Study Datasets

False

Has Specimens

True

Specimen ID Type

Coded

Study Website

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Clinical Trial URLs
N/A
Study type

Epidemiology Study

Collection Type

Open BioLINCC Study

Cohort type

Adult

Interventions

Study Open Date (Data)

None

Study Open Date (Specimens)

2014-05-14

Date materials available

2014-05-12

Last updated

2014-05-12

Study period

09/2009 – 08/2011

Study Contacts
NHLBI Division

DBDR

Classification

Transfusion Medicine

HIV study classification

non-HIV

COVID study classification

non-COVID

Pre-Website # of Specimens Shipped

0

# of Returned Specimens

0

Primary Publication URLs
https://www.ncbi.nlm.nih.gov/pubmed/23209411
Conditions

Blood Donors
Infection
West Nile Virus

Objectives

The goal of the study was to enroll West Nile Virus (WNV) viremic donors into longitudinal natural history study, and characterize viral and immunological parameters.

Background

WNV is the third most important mosquito-borne virus after malaria and dengue virus. Humans are infected by mosquito bites, blood transfusion and organ transplantation. While most infections are asymptomatic or mild, causing a self-limiting febrile illness, the young, old and immunocompromised individuals are at greater risk for severe, sometimes fatal disease. WNV first appeared in the US in 1999 raising concerns for blood supply safety. In the US epidemic of 2002 there were 23 cases of transfusion-transmitted infections (Pealer et al., NEJM 2003). The virus has spread rapidly across the US such that by the end of 2003 there were 19,000 documented cases of WNV infections in the US with 750 fatalities. Testing the blood supply was implemented in 2003. By 2013, 12 transfusion-associated WNV transmissions have been documented in the US.

Participants

A total of 63 WNV+ subjects, of which 54 WNV+ had symptom questionnaires and longitudinal samples collected for characterization and inclusion in the database and repository. Approximately half the subjects developed symptomatic disease based on the study criteria.

Design

The subjects were identified when they presented themselves for blood donation and tested positive for WNV by nucleic acid testing (NAT). They were then contacted and enrolled in the study. On or around week 2 post blood donation, the subjects completed symptom questionnaires and provided a blood sample. Blood samples were also collected on weeks 3, 4, 6, 8, 12, and at 6, 9 and 12 months following the donation of the initial WNV+ blood donation that tested. Immunologic and viral studies were performed on the blood samples and aliquots were stored in the sample repository.

Conclusions

Disease classification

Publications

Mat types

Packed Cells
Peripheral Blood Mononuclear Cells
Plasma
Whole Blood

Network

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types

    Last Modified: Nov. 30, 2015, 4:09 p.m.
  • General Freeze/Thaw Status
  • Visits (Vials)

    10/19/2017

     PlasmaPacked CellsWhole BloodPBMCTotal
    Index5319800629
    Week 151842365181114
    Week 261352365231224
    Week 355952365591206
    Week 459644375651242
    Week 653050376121229
    Month 254848345541184
    Month 348233305531098
    Month 643956345351064
    Month 946379324491023
    Month 1243773304891029


     


    Last Modified: Feb. 13, 2024, 11:05 a.m.
  • Visits (Subjects)

    10/19/2017

     Plasma
    Total number of subjectsAverage volume (ml) per subject
    Index3827.87
    Week 15417.11
    Week 25420.20
    Week 35318.85
    Week 45320.06
    Week 65317.82
    Month 24919.06
    Month 34519.08
    Month 64716.64
    Month 94717.63
    Month 124616.89

     

     Whole Blood
    Total number of subjectsAverage volume (ml) per subject
    Week 1367.83
    Week 2367.81
    Week 3367.78
    Week 4377.84
    Week 6377.81
    Month 2347.79
    Month 3307.87
    Month 6347.88
    Month 9327.63
    Month 12307.67

     

     Packed Cells
    Total number of subjectsAverage vials per subject
    Index372.65
    Week 1421.00
    Week 2521.00
    Week 3521.00
    Week 4441.00
    Week 6501.00
    Month 2481.00
    Month 3331.00
    Month 6411.37
    Month 9471.68
    Month 12431.70

     

     PBMC
    Total number of subjectsAverage vials per subject
    Week 1549.59
    Week 2549.69
    Week 35310.55
    Week 45310.66
    Week 65311.55
    Month 24911.31
    Month 34512.29
    Month 64711.38
    Month 9479.55
    Month 124610.63

    Last Modified: Feb. 13, 2024, 11:06 a.m.